VYNE Therapeutics Inc. (VYNE)
VYNE Therapeutics Inc.
685 Route 202/206 N
Suite 301
Bridgewater, NJ 08807
United States
800 775 7936
https://www.vynetherapeutics.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 10
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. David T. Domzalski | CEO, President & Director | 1.61M | N/D | 1967 |
| Dr. Iain A. Stuart Ph.D. | Chief Scientific Officer | 856.82k | N/D | 1973 |
| Ms. Mutya Harsch J.D. | General Counsel, Chief Legal Officer & Company Secretary | 817.97k | N/D | 1975 |
| Mr. Tyler Zeronda | CFO & Treasurer | N/D | N/D | 1987 |
| Dr. Darrell S. Rigel FAAD, M.D. | Consultant | 40.2k | N/D | 1951 |
Descripción
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor for the treatment of immuno-inflammatory indications. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Gestión corporativa
La calificación ISS Governance QuickScore de VYNE Therapeutics Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
